NCT04226261

Next Generation Pathogen Sequencing for Prediction of Infection in Rheumatic Disease

Status unknown Last updated 13 January 2020

What this trial tests

trial in Infection in 200 participants. Status unknown.

Timeline

15 January 2020

Primary endpoint
15 January 2021

15 June 2021

Quick facts

Lead sponsor	Peking University People's Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	200
Start date	15 January 2020
Primary completion	15 January 2021
Estimated completion	15 June 2021

Conditions studied

• Infection — all drugs for Infection →

Sponsor

Peking University People's Hospital

Who can join

Adults 16 to 70, any sex, with Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The majority of patients diagnosed with rheumatic disease, such as systemic lupus erythematosus, inflammatory myositis, and vasculitis, will experience fever or infection during their course of therapy. The most common microbiologically documented infection is bacterial, virus, and fungal, which can be associated with the severity and mortality of disease. Current methods of diagnosis require a significant load of pathogen making early detection difficult. Delayed diagnosis and delayed optimal therapy of infection are associated with increased morbidity and mortality.

This study seeks to identify whether next generation sequencing (NGS) of pathogens can identify patients with infection treated with corticosteroid and immunosuppressive agents. This would enable preemptive targeted therapy to replace prophylaxis treatment which often leads to some adverse events and antibiotic resistance.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.